Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, April 1, 2017

5 Things to Know About the New MS Medication: Ocrevus (TM) (Ocrelizumab)

Click here to receive MS news via e-mail

Ocrevus (ocrelizumab) for Primary Progressive and Relapsing MS 
Ocrevus will be used for treating primary progressive MS. 
In clinical trials, Ocrevus was found to slow the progress of disability in primary progressive multiple sclerosis (PPMS), which accounts for approximately 10 percent of MS patients.
Ocrevus will also be used for treating relapsing MS patients. 
Ocrevus was found to slow disease activity in more patients taking the drug compared to those who were taking Rebif.
Ocrevus targets myelin-attacking B-cells. 
Ocrevus is an anti-CD20 monoclonal antibody which works by targeting the mature B-cells which contribute to demyelination and damage to nerve cells. Most MS medications currently available work by targeting T-cells. This is one of the only medications that attacks these specific B-cells.
The outcome of the clinical trials. 
More than 1,600 MS patients participated in clinical trials for Ocrevus and 94 percent of participants had fewer brain lesions during the 96 weeks of treatment.
There was little increased risk of infection. 
The clinical trials for Ocrevus also found that while patients taking the drug did have a slightly increased risk of common colds and flu, they had no significant increased risk of other infections when compared to patients taking the alternative medication, Rebif.
Read more from MultipleSclerosisNewsToday

MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

No comments: